Head and neck cancer: Reduce and integrate for optimal outcome

Cytogenetic and Genome Research

Volumn 118, Issue 2-4, 2007, Pages 92-109

  Belbin, T J ^a   Bergman, A ^a   Brandwein Gensler, M ^a   Chen, Q ^a   Childs, G ^a   Garg, M ^a   Haigentz, M ^a   Hogue Angeletti, R ^a   Moadel, R ^a   Negassa, A ^a   Owen, R ^a   Prystowsky, M B ^a   Schiff, B ^a   Schlecht, N F ^a   Shifteh, K ^a   Smith, R V ^a   Zheng, X ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA;

CARCINOGENESIS; DATA ANALYSIS; EPIGENETICS; GENE EXPRESSION; HEAD AND NECK CANCER; HISTOPATHOLOGY; INFORMATION PROCESSING; MUTATION; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; TISSUE MICROARRAY; TUMOR CLASSIFICATION; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 36248933767     PISSN: 14248581     EISSN: None     Source Type: Journal    
DOI: 10.1159/000108290     Document Type: Review

References (150)

1. Adrien LR, Schlecht NF, Kawachi N, Smith RV, Brandwein-Gensler M, et al: Classification of DNA methylation patterns in tumor cell genomes using a CpG island microarray. Cytogenet Genome Res 114:16-23 (2006).
2. Angus SP, Mayhew CN, Solomon DA, Braden WA, Markey MP, et al: RB reversibly inhibits DNA replication via two temporally distinct mechanisms. Mol Cell Biol 24:5404-5420 (2004).
3. Anneroth G, Batsakis J, Luna M: Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Scand J Dent Res 95:229-249 (1987).
4. Bariol C, Suter C, Cheong K, Ku SL, Meagher A, et al: The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am J Pathol 162:1361-1371 (2003).
5. Barnes L, Verbin R, Guggenheimer J: Cancer of the oral cavity and oropharynx, in Barnes L (ed): Surgical Pathology of the Head and Neck, 2nd ed, pp 370-438 (Marcel Dekker, New York 2001).
6. Beitler JJ, Smith RV, Owen RP, Silver CE, Mazumdar M, Wadler S: Phase II clinical trial of parenteral hydroxyurea and hyperfractionated, accelerated external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck: Toxicity and efficacy with continuous ribonucleoside reductase inhibition. Head Neck 29:18-25 (2007).
7. Belbin TJ, Singh B, Barber I, Socci N, Wenig B, et al: Molecular classification of head and neck squamous cell carcinoma using cDNA microarrays. Cancer Res 62:1184-1190 (2002).
8. Belbin TJ, Gaspar J, Haigentz M, Perez-Soler R, Keller SM, et al: Indirect measurements of differential gene expression with cDNA microarrays. Biotechniques 36:310-314 (2004).
9. Belbin TJ, Singh B, Smith RV, Socci ND, Wreesmann VB, et al: Molecular profiling of tumor progression in head and neck cancer. Arch Otolaryngol Head Neck Surg 131:10-18 (2005).
10. Benjamini Y, Yekutieli D: Quantitative trait loci analysis using the false discovery rate. Genetics 171:783-790 (2005).
11. Bergman A, Siegal ML: Evolutionary capacitance as a general feature of complex gene networks. Nature 424:549-552 (2003).
12. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, et al: Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945-1952 (2004).
13. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578 (2006).
14. Brandwein-Gensler M, Teixeira MS, Lewis CM, Lee B, Rolnitzky L, et al: Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 29:167-178 (2005).
15. Breiman L, Friedman J, Olshen R, Stone C: Classification and Regression Trees (Wadsworth International Group, Belmont 1984).
16. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, et al: Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345 (2000).
17. Bryne M, Koppang HS, Lilleng R, Stene T, Bang G, Dabelsteen E: New malignancy grading is a better prognostic indicator than Broders' grading in oral squamous cell carcinomas. J Oral Pathol Med 18:432-437 (1989).
18. Bryne M, Koppang HS, Lilleng R, Kjaerheim A: Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J Pathol 166:375-381 (1992).
19. Bryne M, Jenssen N, Boysen M: Histological grading in the deep invasive front of T1 and T2 glottic squamous cell carcinomas has high prognostic value. Virchows Arch 427:277-281 (1995).
20. Bundgaard T, Rossen K, Henriksen SD, Charabi S, Sogaard H, Grau C: Histopathologic parameters in the evaluation of T1 squamous cell carcinomas of the oral cavity. Head Neck 24:656-660 (2002).
21. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, et al: Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91:2081-2086 (1999).
22. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, et al: Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56:2488-2492 (1996).
23. Calin GA, Croce CM: MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 25:6202-6210 (2006a).
24. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6:857-866 (2006b).
25. Cao QJ, Belbin T, Socci N, Balan R, Prystowsky MB, et al: Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium. Int J Gynecol Pathol 23:321-329 (2004).
26. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP: Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 114:806-816 (2005).
27. Cheung VG, Morley M, Aguilar F, Massimi A, Kucherlapati R, Childs G: Making and reading microarrays. Nat Genet 21:15-19 (1999).
28. Ciampi A, Negassa A, Lou Z: Tree-structured prediction for censored survival data and the Cox model. J Clin Epidemiol 48:675-689 (1995).
29. Condeelis J, Pollard JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124:263-266 (2006).
30. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, et al: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937-1944 (2004).
31. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, et al: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24:132-138 (2000).
32. Couzin J: Breakthrough of the year. Small RNAs make big splash. Science 298:2296-2297 (2002).
33. Cummins JM, Velculescu VE: Implications of micro-RNA profiling for cancer diagnosis. Oncogene 25:6220-6227 (2006).
34. De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, Nuyts S: The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer 5:42 (2005).
35. Dombrowski SM, Maglott D: Using the map viewer to explore genomes, in: The NCBI handbook [Internet], Chapter 19 (National Library of Medicine (US), National Center for Biotechnology Information, Bethesda 2003).
36. Dudoit S, Fridlyand J: A prediction-based resampling method for estimating the number of clusters in a dataset. Genome Biol 3:RESEARCH0036 (2002).
37. Eisen MB, Spellman PT, Brown PO, Botstein D: Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95:14863-14868 (1998).
38. Epstein JB, Robertson M, Emerton S, Phillips N, Stevenson-Moore P: Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck 23:389-398 (2001).
39. Eriksen JG, Steiniche T, Overgaard J: The role of epidermal growth factor receptor and E-cadherin for the outcome of reduction in the overall treatment time of radiotherapy of supraglottic larynx squamous cell carcinoma. Acta Oncol 44:50-58 (2005).
40. Ferlay J, Bray F, Pissani P, Parkin DM: GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC Cancer-Base No. 5 (IARC Press, Lyon 2001).
41. Forastiere A, Koch W, Trotti A, Sidransky D: Head and neck cancer. N Engl J Med 345:1890-1900 (2001).
42. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098 (2003).
43. Gal TJ, Yueh B, Futran ND: Influence of prior hyperbaric oxygen therapy in complications following microvascular reconstruction for advanced osteoradionecrosis. Arch Otolaryngol Head Neck Surg 129:72-76 (2003).
44. George E, McCulloch R: Variable selection via Gibbs sampling. JASA 88:881-889 (1993).
45. Gillison ML, Shah KV: Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol 13:183-188 (2001).
46. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709-720 (2000).
47. Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, et al: Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 64:55-63 (2004).
48. Hanna E, Shrieve DC, Ratanatharathorn V, Xia X, Breau R, et al: A novel alternative approach for prediction of radiation response of squamous cell carcinoma of head and neck. Cancer Res 61:2376-2380 (2001).
49. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, et al: Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 95:1772-1783 (2003).
50. Hochberg Y, Benjamini Y: More powerful procedures for multiple significance testing. Stat Med 9:811-818 (1990).
51. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57:43-66 (2007).
52. Joost HG, Thorens B: The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review). Mol Membr Biol 18:247-256 (2001).
53. Kapil U, Singh P, Bahadur S, Dwivedi SN, Singh R, Shukla N: Assessment of risk factors in laryngeal cancer in India: a case-control study. Asian Pac J Cancer Prev 6:202-207 (2005).
54. Khuri FR, Jain SR: Novel agents and incremental advances in the treatment of head and neck cancer. Semin Oncol 31:3-10 (2004).
55. Kim HC, Kusukawa J, Kameyama T: Clinicopathologic parameters in predicting cervical nodal metastasis in early squamous cell carcinoma of the oral cavity. Kurume Med J 40:183-192 (1993).
56. Kobayashi H, Sagara J, Kurita H, Morifuji M, Ohishi M, et al: Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. Clin Cancer Res 10:572-580 (2004).
57. Koch WM, Lango M, Sewell D, Zahurak M, Sidransky D: Head and neck cancer in nonsmokers: a distinct clinical and molecular entity. Laryngoscope 109:1544-1551 (1999).
58. Koh DM, Padhani AR: Diffusion-weighted MRI: a new functional clinical technique for tumour imaging. Br J Radiol 79:633-635 (2006).
59. Kudo Y, Kitajima S, Ogawa I, Hiraoka M, Sargolzaei S, et al: Invasion and metastasis of oral cancer cells require methylation of E-cadherin and/or degradation of membranous beta-catenin. Clin Cancer Res 10:5455-5463 (2004).
60. Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, et al: Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97:1015-1024 (2003).
61. Kyzas PA, Loizou KT, Ioannidis JP: Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 97:1043-1055 (2005).
62. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T: Identification of novel genes coding for small expressed RNAs. Science 294:853-858 (2001).
63. Lau NC, Lim LP, Weinstein EG, Bartel DP: An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294:858-862 (2001).
64. Lee RC, Ambros V: An extensive class of small RNAs in Caenorhabditis elegans. Science 294:862-864 (2001).
65. Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843-854 (1993).
66. Lee SH, Kwong AD, Pan ZQ, Hurwitz J: Studies on the activator 1 protein complex, an accessory factor for proliferating cell nuclear antigen-dependent DNA polymerase delta. J Biol Chem 266:594-602 (1991).
67. Leethanakul C, Patel V, Gillespie J, Pallente M, Ensley JF, et al: Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays. Oncogene 19:3220-3224 (2000).
68. Leitha T, Glaser C, Lang S: Is early sestamibi imaging in head and neck cancer affected by MDR status, p53 expression, or cell proliferation? Nucl Med Biol 25:539-541 (1998).
69. Lindberg R: Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 29:1446-1449 (1972).
70. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM: Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 92:805-813 (2001).
71. List MA, Bilir SP: Evaluations of quality of life and organ function. Semin Oncol 31:827-835 (2004).
72. Liu ZJ, Maekawa M: Polymerase chain reaction-based methods of DNA methylation analysis. Anal Biochem 317:259-265 (2003).
73. Lothaire P, de Azambuja E, Dequanter D, Lalami Y, Sotiriou C, et al: Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation. Head Neck 28:256-269 (2006).
74. Lu J, Getz G, Miska EA, varez-Saavedra E, Lamb J, et al: MicroRNA expression profiles classify human cancers. Nature 435:834-838 (2005).
75. Madan R, Brandwein-Gensler M, Schlecht NF, Elias K, Gorbovitsky E, et al: Differential tissue and subcellular expression of ERM proteins in normal and malignant tissues: cytoplasmic ezrin expression has prognostic signficance for head and neck squamous cell carcinoma. Head Neck 28:1018-1027 (2006).
76. Mangeat P, Roy C, Martin M: ERM proteins in cell adhesion and membrane dynamics. Trends Cell Biol 9:187-192 (1999).
77. Martinez I, Wang J, Hobson KF, Ferris RL, Khan SA: Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer 43:415-432 (2006).
78. Martinez-Gimeno C, Rodriguez EM, Vila CN, Varela CL: Squamous cell carcinoma of the oral cavity: a clinicopathologic scoring system for evaluating risk of cervical lymph node metastasis. Laryngoscope 105:728-733 (1995).
79. Maruya S, Issa JP, Weber RS, Rosenthal DI, Haviland JC, et al: Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin Cancer Res 10:3825-3830 (2004).
80. McShane LM, Altman DG, Sauerbrei W: Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Inst 97:1023-1025 (2005a).
81. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180-1184 (2005b).
82. Mellanen P, Minn H, Grenman R, Harkonen P: Expression of glucose transporters in head-and-neck tumors. Int J Cancer 56:622-629 (1994).
83. Mineta H, Miura K, Takebayashi S, Misawa K, Araki K, et al: Prognostic value of glucose transporter 1 expression in patients with hypopharyngeal carcinoma. Anticancer Res 22:3489-3494 (2002).
84. Mubashar M, Harrington KJ, Chaudhary KS, Lalani el-N, Stamp GW, Peters AM: Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines. Acta Oncol 43:443-452 (2004).
85. Negassa A, Ciampi A, Abrahamowicz M, Shapiro S, Boivin J: Validation of tree structured prediction for censored survival data: Its application to prognstic classification. J Statist Comput Simul 67:289-317 (2000).
86. Neiderhuber J: First-Generation Guidelines for NCI-Supported Biorepositories. Federal Register 71:25184-25203 (2006).
87. Ng IO, Lam KY, Ng M, Kwong DL, Sham JS: Expression of P-glycoprotein, a multidrug-resistance gene product, is induced by radiotherapy in patients with oral squamous cell carcinoma. Cancer 83:851-857 (1998).
88. Novoradovskaya N, Whitfield ML, Basehore LS, Novoradovsky A, Pesich R, et al: Universal Reference RNA as a standard for microarray experiments. BMC Genomics 5:20 (2004).
89. Ogi K, Toyota M, Ohe-Toyota M, Tanaka N, Noguchi M, et al: Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res 8:3164-3171 (2002).
90. Oliver RJ, Woodwards RT, Sloan P, Thakker NS, Stratford IJ, Airley RE: Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection; results of EORTC Translational Research Fund studies. Eur J Cancer 40:503-507 (2004).
91. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, et al: MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer 13:497-508 (2006).
92. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Molecular portraits of human breast tumours. Nature 406:747-752 (2000).
93. Pignon JP, Burdett S: Comment on 'Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature' by T. Berghmans, M. Paesmans, A.P. Meert, C. Mascaux, P. Lothaire, J.J. Lafitte, et al. (Lung Cancer 49 (2005) 13-23.) Lung Cancer 51:261-262 (2006).
94. Pignon JP, Bourhis J, Domenge C, Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355:949-955 (2000).
95. Po Wing YA, Lam KY, Lam LK, Ho CM, Wong A, et al: Prognostic factors of clinically stage I and II oral tongue carcinoma-A comparative study of stage, thickness, shape, growth pattern, invasive front malignancy grading, Martinez-Gimeno score, and pathologic features. Head Neck 24:513-520 (2002).
96. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, et al: Genomic signatures to guide the use of chemotherapeutics. Nat Med 12:1294-1300 (2006).
97. Puskas LG, Zvara A, Hackler L, Jr., Micsik T, van HP: Production of bulk amounts of universal RNA for DNA microarrays. Biotechniques 33:898-900, 902, 904 (2002).
98. Rabkin D, Chhieng DC, Miller MB, Jennings T, Feustel P, et al: P-glycoprotein expression in the squamous cell carcinoma of the tongue base. Laryngoscope 105:1294-1299 (1995).
99. Ragin CC, Taioli E, Weissfeld JL, White JS, Rossie KM, et al: 11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours. Br J Cancer 95:1432-1438 (2006).
100. Reiner A, Yekutieli D, Benjamini Y: Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19:368-375 (2003).
101. Reisser C, Eichhorn K, Herold-Mende C, Born AI, Bannasch P: Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer 80:194-198 (1999).
102. Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M: Tissue microarray: a new technology for amplification of tissue resources. Cancer J 7:24-31 (2001).
103. Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang D, et al: Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 104:336-344 (2003).
104. Robertson KD: DNA methylation, methyltransferases, and cancer. Oncogene 20:3139-3155 (2001).
105. Roesch-Ely M, Nees M, Karsai S, Ruess A, Bogumil R, et al: Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer. Oncogene 26:54-64 (2006).
106. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684 (2005).
107. Rosas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, et al: Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 61:939-942 (2001).
108. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, et al: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9:435-443 (2006).
109. Schlecht NF: Prognostic value of human papillomavirus in the survival of head and neck cancer patients: an overview of the evidence. Oncol Rep 14:1239-1247 (2005).
110. Schlecht NF, Franco EL, Pintos J, Negassa A, Kowalski LP, et al: Interaction between tobacco and alcohol consumption and the risk of cancers of the upper aero-digestive tract in Brazil. Am J Epidemiol 150:1129-1137 (1999).
111. Schwartz GJ, Mehta RH, Wenig BL, Shaligram C, Portugal LG: Salvage treatment for recurrent squamous cell carcinoma of the oral cavity. Head Neck 22:34-41 (2000).
112. Schwartz SM, Daling JR, Doody DR, Wipf GC, Carter JJ, et al: Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 90:1626-1636 (1998).
113. Shrout P, Fleiss J: Intraclass correlation: Uses in assessing rater reliability. Psychol Bull 86:420-428 (1979).
114. Siegal ML, Bergman A: Waddington's canalization revisited: developmental stability and evolution. Proc Natl Acad Sci USA 99:10528-10532 (2002).
115. Simon R, Radmacher MD, Dobbin K: Design of studies using DNA microarrays. Genet Epidemiol 23:21-36 (2002).
116. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182 (1987).
117. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792 (2001).
118. Slebos RJ, Yi Y, Ely K, Carter J, Evjen A, et al: Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 12:701-709 (2006).
119. Smith EM, Ritchie JM, Summersgill KF, Hoffman HT, Wang DH, et al: Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 96:449-455 (2004).
120. Smith EM, Ritchie JM, Pawlita M, Rubenstein LM, Haugen TH, et al: Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer 120:825-832 (2006).
121. Smith RV, Goldman SY, Beitler JJ, Wadler SS: Decreased short- and long-term swallowing problems with altered radiotherapy dosing used in an organ-sparing protocol for advanced pharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 130:831-836 (2004).
122. Smith RV, Schlecht NF, Childs G, Prystowsky MB, Belbin TJ: Pilot study of mucosal genetic differences in early smokers and nonsmokers. Laryngoscope 116:1375-1379 (2006).
123. Spiro RH, Guillamondegui O, Jr, Paulino AF, Huvos AG: Pattern of invasion and margin assessment in patients with oral tongue cancer. Head Neck 21:408-413 (1999).
124. Storey JD: A direct approach to false discovery rates. J R Stat Soc B 64:479-498 (2002).
125. Strati K, Pitot HC, Lambert PF: Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci USA 103:14152-14157 (2006).
126. Takes RP, Baatenburg de Jong RJ, Schuuring E, Hermans J, Vis AA, et al: Markers for assessment of nodal metastasis in laryngeal carcinoma. Arch Otolaryngol Head Neck Surg 123:412-419 (1997).
127. Tibshirani R, Hastie T, Narasimhan B, Chu G: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99:6567-6572 (2002).
128. Tseng GC, Oh MK, Rohlin L, Liao JC, Wong WH: Issues in cDNA microarray analysis: quality filtering, channel normalization, models of variations and assessment of gene effects. Nucleic Acids Res 29:2549-2557 (2001).
129. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121 (2001).
130. Vandecaveye V, de Keyzer F, Vander Poorten V, Deraedt K, Alaerts H, et al: Evaluation of the larynx for tumour recurrence by diffusion-weighted MRI after radiotherapy: initial experience in four cases. Br J Radiol 79:681-687 (2006).
131. van de Vijver M, He YD, van 't Veer LJ, Dai H, Hart AA, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009 (2002).
132. van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B: CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 9:2898-2903 (2003).
133. van 't Veer L, Dai H, van de Vijver MJ, He YD, Hart AA, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536 (2002).
134. Villaret DB, Wang T, Dillon D, Xu J, Sivam D, et al: Identification of genes overexpressed in head and neck squamous cell carcinoma using a combination of complementary DNA subtraction and microarray analysis. Laryngoscope 110:374-381 (2000).
135. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103:2257-2261 (2006).
136. Wang J, Takashima S, Takayama F, Kawakami S, Saito A, et al: Head and neck lesions: characterization with diffusion-weighted echo-planar MR imaging. Radiology 220:621-630 (2001).
137. Warner GD, Reis PP, Jurisica I, Sultan M, Arora S, et al: Molecular classification of oral cancer by cDNA microarrays identifies overexpressed genes correlated with nodal metastasis. Int J Cancer 110:857-868 (2004).
138. Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, et al: Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 8:2246-2252 (2002).
139. Xiao GH, Beeser A, Chernoff J, Testa JR: p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem 277:883-886 (2002).
140. Yan PS, Perry MR, Laux DE, Asare AL, Caldwell CW, Huang TH: CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. Clin Cancer Res 6:1432-1438 (2000).
141. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9:189-198 (2006).
142. Yang YH, Speed T: Design issues for cDNA microarray experiments. Nat Rev Genet 3:579-588 (2002).
143. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, et al: Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30:e15 (2002).
144. Yarbrough WG, Slebos RJ, Liebler D: Proteomics: clinical applications for head and neck squamous cell carcinoma. Head Neck 28:549-558 (2006).
145. Yonemura S, Hirao M, Doi Y, Takahashi N, Kondo T, et al: Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol 140:885-895 (1998).
146. Yonemura S, Tsukita S, Tsukita S: Direct involvement of ezrin/radixin/moesin (ERM)-binding membrane proteins in the organization of microvilli in collaboration with activated ERM proteins. J Cell Biol 145:1497-1509 (1999).
147. Yoo GH, Piechocki MP, Ensley JF, Nguyen T, Oliver J, et al: Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Clin Cancer Res 8:3910-3921 (2002).
148. Yu T, Robb VA, Singh V, Gutmann DH, Newsham IF: The 4.1/ezrin/radixin/ moesin domain of the DAL-1/Protein 4.1B tumour suppressor interacts with 14-3-3 proteins. Biochem J 365:783-789 (2002).
149. Zhang B, Pan X, Cobb GP, Anderson TA: micro-RNAs as oncogenes and tumor suppressors. Dev Biol 302:1-12 (2006).
150. Zuo C, Ai L, Ratliff P, Suen JY, Hanna E, et al: O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 13:967-975 (2004).